(19)
(11) EP 2 653 873 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.08.2022 Bulletin 2022/34

(45) Mention of the grant of the patent:
20.07.2022 Bulletin 2022/29

(21) Application number: 13169139.6

(22) Date of filing: 07.02.2008
(51) International Patent Classification (IPC): 
G01N 33/68(2006.01)
 G01N 33/50(2006.01)
(52) Cooperative Patent Classification (CPC):
G01N 33/502; G01N 2333/90209; G01N 2800/285; A61K 38/217; A61K 45/06; A61K 31/436; A61K 31/137; A61K 31/194; A61K 31/197; A61K 31/277; A61K 31/4704; A61K 31/7076; A61K 31/225; A61P 25/00; A61P 25/28
 
C-Sets:
A61K 31/194, A61K 2300/00;

(54)

Compositions and uses for treating Multiple Sclerosis

Zusammensetzungen und deren Verwendung zur Behandlung von Multipler Sklerose

Compositions et leurs utilisations pour le traitement de la Sclérose en plaques

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA MK RS

(30) Priority: 08.02.2007 US 888921 P

(43) Date of publication of application:
23.10.2013 Bulletin 2013/43

(60) Divisional application:
22185834.3

(62) Application number of the earlier application in accordance with Art. 76 EPC:
08725256.5 / 2137537

(73) Proprietor: Biogen MA Inc.
Cambridge, MA 02142 (US)

(72) Inventors:
  • Lukashev, Matvey, E.
    Tewksbury, MA 01876 (US)
  • O'Neill, Gilmore
    Medford, MA 02155 (US)

(74) Representative: Pohlman, Sandra M. 
df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte PartG mbB Theatinerstrasse 16
80333 München
80333 München (DE)


(56) References cited: : 
   
  • SCHIMRIGK S ET AL: "Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study", EUROPEAN JOURNAL OF NEUROLOGY, vol. 13, no. 6, June 2006 (2006-06), pages 604-610, XP002496537, ISSN: 1351-5101
  • SCHILLING S ET AL: "Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 145, no. 1, 1 July 2006 (2006-07-01), pages 101-107, XP009105979, ISSN: 0009-9104, DOI: 10.1111/J.1365-2249.2006.03094.X
  • GOLD R ET AL: "Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, SPRINGER VERLAG, BERLIN, DE, vol. 253, no. Suppl. 2, 1 May 2006 (2006-05-01), pages II144-II145, XP009157336, ISSN: 0340-5354
  • KAPPOS L ET AL: "BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis", MULTIPLE SCLEROSIS, SAGE PUBLICATIONS, BASINGSTOKE, GB, vol. 12, no. Suppl. 1, 1 January 2006 (2006-01-01), page S85, XP009157337, ISSN: 1352-4585
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).